Context: De novo brain tumors developing after treatment of pituitary/sellar lesions have been reported, but it is unknown whether this is linked to any of the treatment modalities.
R adiotherapy (RT) has been used for many years as adjunctive treatment to surgery for benign pituitary tumors. Whereas development of hypopituitarism is a well-described late-stage consequence, there is limited information on a severe type of radiotoxicity-induction of a brain tumor. Three studies on small groups of patients who underwent both surgery and RT have reported an increased incidence of malignant brain tumors (1-3), whereas two other studies did not find a significant excess compared with controls (4, 5) . The causative effect of RT has been questioned (3, 6, 7) because only healthy subjects were used as comparators in these studies. A potential genetic link between pituitary adenomas and independent primary tumors of other origin, as reported by Popovic et al. (8) and Couldwell and Cannon-Albright (9) , might provide an alternative explanation. Another three previous studies have used patients with pituitary tumors not treated with RT as the comparator (6, 10, 11) . Although de novo brain tumors were observed in irradiated patients in one of the studies, with 5 cases vs an expected 1.15 corresponding to a standardized incidence ratio (SIR) of 5.20 (range, 1.90 to 11.31) (10) , there was no difference between the treatment groups in the other two (6, 11) . The number of patients in these three studies combined was 981 in the RT groups and 707 in the surgeryonly groups, and therefore they potentially lack power to detect a difference. Although RT is plausible in the etiology of secondary tumors, other patient-and treatment-related factors have to be taken into account. In this clinical/ observational setting it has proven difficult to implicate risk factors for brain tumor induction, because disease incidence is low and mostly after decades, and previous study populations were small.
To circumvent these problems, we examined a large cohort of 8917 patients with pituitary tumors treated with and without RT. Our aim was to study the incidence of de novo brain tumors, benign and malignant, in the two treatment groups as well as in reference to general population rates, and to analyze potential risk factors for tumor development.
Patients and Methods
Between 1994 and June 2012, 16,484 adult patients with growth hormone (GH) deficiency (GHD) were enrolled in the global KIMS (Pfizer International Metabolic Database). All patients included in this study (n = 8917) had been treated for benign pituitary tumors, craniopharyngiomas, and other sellar tumors. The patients were from 31 countries, of which seven had enrolled .450 patients each: Germany, United Kingdom, United States, Sweden, Spain, Belgium, and The Netherlands. The time from KIMS entry to last follow-up was in median 5.3 years (range, 0 to 18.3), representing a total of 53,786 patient-years.
The normal routine in KIMS was that the treating physician reported a tumor as an adverse event and wrote a comment in free text. In the present study, all event reports on brain tumors were re-examined in detail by the authors. Four events initially classified as primary malignant brain tumors appeared to be on reassessment pituitary carcinomas with brain metastases (n = 2), other brain metastases (n = 1), and recurrent germ cell tumor (n = 1). These malignancies were subsequently excluded as cases from the present analysis.
The type of RT was reported to KIMS as conventional external, radioactive implants, gamma knife, conformal RT, and stereotactic RT not further specified. In the analysis, conformal RT and stereotactic RT not further specified were handled as stereotactic RT, resulting in four different RT categories: conventional external, radioactive implants, gamma knife, and stereotactic RT.
Details regarding the type and mode of RT delivery were requested through questionnaires sent to the investigators; no additional information was available. Information about treatment of the underlying etiology was missing in 754 of the 8917 patients. No brain tumor was reported in this group.
Statistical methods
For descriptive statistics, means and standard deviations (SDs) or median with 1st and 99th percentile (range) or proportions (percentages) were calculated depending on the type of variable.
SIRs, which compare observed number of cases in the patient group and the expected number of cases, were calculated using stratification for attained age, sex, and country. The latter number quantifies the number of expected cases in the patient group and whether the patient group had the same specific rates as the chosen external reference population (12) . Patient-years were calculated from the date of KIMS entry or GH start date (if later than KIMS entry date) to the date of the studied event, or if no event, the date of the last visit or date of death, stratified for attained age, sex, and country.
For internal reference analyses the same stratifications of patient-years were used as for the external analyses and incidence rate ratios (RRs, which represent relative risks) were analyzed. Multiple Poisson regression analyses were performed testing the risk factors of interest, which were sex, attained age 2 ), and luteinizing hormone (LH)/follicle-stimulating hormone (FSH) deficiency or hormone substitution in females at KIMS entry (yes vs no). For testing GH dose and insulin-like growth factor I (IGF-I) SD score (SDS) (13) , Cox regression with numerical time-dependent covariates were applied. The 95% confidence intervals (CIs) for SIRs were calculated with Byar's approximation equation (14) .
In the internal reference Poisson regression models, CIs and P values were based on likelihood methods. P values of #0.05 were considered statistically significant. For one analysis (LH/ FSH deficiency) where there were no cases in the reference group, the rate difference was calculated with Byar's formula for the 95% CI (14) . Analyses were performed with SAS 9.4.
Results
The etiology of the 8917 pituitary tumors/sellar lesions was as follows: pituitary adenomas n = 6750 (including 3751 nonfunctioning adenomas, 1308 prolactinomas, 903 ACTH-secreting adenomas, 362 adenomas not further specified, 253 GH-secreting adenomas, 109 FSH/ LH-secreting adenomas, 38 thyrotropin-secreting adenomas, and 26 adenomas secreting multiple hormones), craniopharyngiomas n = 1670, germ cell tumors n = 262, cystic lesions n = 222, and hamartomas n = 13 (details are provided in Table 1 ). Fifty-four percent of the patients were men, and 89% had an adult onset of GHD. The age of the patients at KIMS entry was median 48 years (range, 18 to 77). Patients who had been treated before 1990 were younger at the time of treatment; median ages for calendar periods ,1990, 1990 to 1999, and $2000 were 30.6, 42.6, and 47.7 years, respectively. RT had been given to 3236 patients (RT group), of which 88.6% had also been treated with surgery. There were 4927 patients who had not received RT (non-RT group); 96% of the patients in this group had undergone surgery. Radiation treatment had been administered between 1954 and 2011 (1497 patients had been treated before 1990, 1363 between 1990 and 1999, and 376 between 2000 and 2011). The median time between treatment of the pituitary sellar lesions to KIMS entry for the three treatment periods were 16.2, 4.6, and 1.4 years, the median observation period in KIMS was 7.0, 6.2 and 3.3 years, and the overall average was 5.4 years (range, 0 to 18), similar for patients treated with RT and not treated with RT. The type of RT was conventional in 2771 patients, stereotactic in 339, gamma knife in 68, radioactive implants in 57, and gamma knife plus radioactive implants in one. In the seven countries that had contributed .450 patients each to the study, the proportion of patients treated with RT was on average 58% before 1990, 42% during 1990 to 1999, and 20% during 2000 to 2011. During the latter decade the use of RT in Germany, Sweden, and the United States spanned from 9% to 12%, in Belgium and the Netherlands from 20% to 27%, and up to 42% in the United Kingdom.
De novo malignant brain tumors
In total, 17 malignant brain tumors were reported in the database (Table 2 ) vs 5.01 expected (SIR, 3.40; 95% CI, 1.98 to 5.44). This excess was clearly observed in the RT group, with 13 observed vs 2.16 expected cases (SIR, 6.02; 95% CI, 3.20 to 10.3), but not in the non-RT group, which had 4 observed cases vs 2.84 expected (SIR, 1.41; 95% CI, 0.38 to 3.60). The RR of developing a malignant brain tumor in the RT group vs non-RT group was 4.12 (95% CI, 1.34 to 12.6; P = 0.013, with non-RT group as reference), with adjustment for attained age and sex. With additional adjustment for the treatment calendar period, the RR was 3.34 (95% CI, 1.06 to 10.6). The median time from first RT to diagnosis of the 13 tumors was 27 years, with a range of 6 to 46 years. The age at diagnosis of the brain tumor was ;10 years lower in the RT group compared with the non-RT group (median, 57.2 years; range, 34.8 to 76.3 years; vs median, 66.9 years; range, 44.1 to 71.6 years). The 17 brain tumors were located in the frontal lobe (n = 4), brain stem (n = 3), temporal lobes (n = 1), caudate nucleus (n = 1), right ventricle (n = 1), cerebellum (n = 1), and location not specified (n = 6).
Meningiomas
In total, 27 meningiomas had been reported. Twentytwo occurred in the RT group, corresponding to 0.98 Meningiomas in the RT group were located in the temporal convexity (n = 4), the frontal region (n = 3, including one frontotemporal and one fronto-orbital region), the parasellar/sphenoidal region (n = 3), multiple sites causing hydrocephalus (n = 1), the parietal convexity (n = 1), above the tentorium (n = 1), in the falx cerebri (n = 1), and not specified (n = 8). In the non-RT group, one was located in the upper thoracic spinal cord, one compressed the trigeminal nerve, and three were in sites not specified. Eight of the 27 meningiomas had required surgery, one was inoperable and the patient treated with analgesics, four were scheduled for further imaging, and in 14 cases the actions taken were not specified.
Age at RT and de novo brain tumors
A younger age at RT was accompanied by a higher risk of developing a malignant brain tumor and meningioma (Fig. 1) . For each younger year of age at RT, the risk of developing a malignant brain tumor increased by 8.2% (95% CI, 2.6% to 13.5%; P = 0.005), and the risk of developing a meningioma increased by 4.6% (95% CI, 0.0% to 9.0%; P = 0.05), controlling for attained age during follow-up and sex.
Calendar period of treatment and risk of RT
A higher number of brain tumors were observed in patients treated during the earlier calendar periods, and the ratios of incidences rates between RT and non-RT groups were similar during the treatment periods (Table 3) .
Type of RT and de novo brain tumors
The incidence rate of brain tumors (malignant plus meningiomas) was similar in patients treated with external RT and stereotactic RT: 1.58/1000 patient-years for the former treatment modality and 1.97/1000 patientyears for the latter treatment modality. There were no de novo brain tumors reported in the smaller groups of patients treated with gamma knife or radioactive implants, except for one malignant brain tumor in a patient who had received a combination of these types of RT. Etiology of the underlying pituitary/sellar lesions, BMI, sex steroid hormone replacement therapy, GH dose, IGF-I SDS, and de novo brain tumors There was no statistically significant association between the etiology of the pituitary tumors and development of brain tumors. The incidences per 1000 patient-years were 0.78 in non-GH-secreting pituitary adenomas, 1.82 in GH-secreting adenomas, and 0.80 in tumors of other etiologies. Likewise, there was no association with BMI and the development of de novo brain tumors (P = 0.89; trend test). Of note was the 18 meningiomas observed during 19,021 patient-years in the group of women with LH/FSH deficiency (rate 0.95/ 1,000 patient-years) vs no cases during 5955 patientyears in the group of women without LH/FSH deficiency. However, relatively more LH/FSH-deficient patients were treated in earlier calendar periods, and age at RT was 3 to 5 years younger in deficient patients (data not shown). Relative risk was not possible to calculate, but the incidence rate difference between groups per 1000 patient-years was 0.95 (95% CI, 0.5 to 1.38; P = 0.015). When contrasting women with estrogen replacement vs those with no reported estrogen replacement, there were nine cases in each category and an incidence per 1000 patient-years of 0.72 and 0.71, respectively (RR, 1.04; 95% CI, 0.41 to 2.68; P = 0.93). There were no differences in GH doses and IGF-I SDS in patients who did and did not develop second brain tumors [mean of 0.38 mg/day (SD 0.28) vs 0.39 mg/day (SD 0.24), P = 0.86, and mean of 0.62 SDS (SD 2.13) vs 0.45 SDS (SD 1.63), P = 0.67, respectively].
Discussion
We found a 3.3-fold higher relative risk of developing de novo malignant brain tumors and a fourfold higher risk of meningiomas in patients who received RT vs those treated without RT. The risk of developing a de novo brain tumor approximately doubled for every 10 years of Figure 1 . The relationship between age at RT and the relative risk of developing de novo brain tumors. Upper part, malignant brain tumors; lower part, meningiomas. Cases, observed numbers of cases. RR indicates incidence rate in the RT vs incidence rate in the non-RT group after adjustment for attained age, sex, and treatment period. PY, patient years. press.endocrine.org/journal/jcemyounger age at the time of RT administration, and it was ;14-fold higher for malignant brain tumors and eightfold higher for meningiomas when RT had been given before 30 years of age. Our data are in agreement with the observed increased sensitivity to an oncogenic effect of RT in patients treated for a variety of childhood cancers (15) . This effect of age can be attributed to a larger proportion of stem cells, higher cellular proliferative rates, and a promotional role of GH (16) . Most patients in the present study had received irradiation with conventional techniques, which use two to three coplanar beams. This results in high doses of radiation to nontumoral tissue in the radiation path, particularly in the temporal lobes of the brain. Some more recent techniques use increased number of beams in different planes. The radiation is delivered with stereotactic guidance either as repeat small doses (i.e., stereotactic RT) or as a single larger dose (i.e., stereotactic radiosurgery) to improve dose distribution within the tumor while sparing the rest of the brain (17) . This has been hypothesized to reduce toxicity, including radiooncogenesis. Whereas the amount of tissue exposed to high doses is reduced with the newer techniques, this is achieved at the expense of increasing the volume of brain that is exposed to lower doses (18) . It is notable that in the present study, the proportion of de novo brain tumors emerging after RT was similar with conventional and stereotactic techniques, but note that the number of patients treated with gamma knife was small.
There are few reports on secondary brain tumors after focused RT such as gamma knife and other stereotactic RT (19) (20) (21) . These techniques allow a better delineation of the target, and they are therefore likely to cause less harm to surrounding nontumoral tissues. However, as the use of these modalities is rather recent, there are fewer exposed patients and more limited duration of follow-up compared with older forms of RT. Thus, conclusions cannot yet be reached about a potential reduction of longterm radiation toxicity. Three larger studies have demonstrated that low doses to the brain can be harmful (22) (23) (24) . Low-dose radiation in childhood (1 to 2 Gy) for treatment of a fungal infection in the scalp was found to increase the incidences of meningiomas and gliomas by 9.5-and 2.6-fold, respectively, at a follow-up ;30 years later (22) . In two other recent studies, repeat CT scans before the age of 20 years resulted in a higher than expected number of solid tumors (23, 24) . Regarding brain cancer, a dose as low as 60 mGy, resulting from three CT scans of the head, was found to triple the risk (23) . Thus, in terms of the oncogenic potential of RT, doses delivered to the brain with modern RT cannot be presumed to be safe, particularly in young subjects, nor can they be presumed to be a risk.
In the previous smaller studies (1-3, 10) the risk of acquiring a malignant brain tumor was higher, 1% to 3% during 15 to 20 years, increasing up to 4.8% at 30 years of follow-up. In the present study, 35 brain tumors (13 malignant and 22 meningiomas) were reported in the database in 3236 irradiated patients, representing 1.1% of the overall population studied. This latter lower percentage is likely due to the shorter median follow-up in the present study and to the differences in the study designs. Others have found a median latency period, that is, time from RT to the time of diagnosis of the brain tumor, of ;9 years for malignant gliomas (25) and ;19 years for meningiomas (26) . The vast majority of malignant gliomas develop within 15 years of RT (25) . In the present study, where RT had been given between 1954 and 2011 and the period of observation spanned 1994 to 2012, the observed latency period seemed longer, with a median of 27 years for the malignant tumors. This apparent delay is likely to reflect survivor bias, as the study design enabled detection of predominantly late-appearing tumors. Furthermore, incidental cases of asymptomatic meningiomas may not have been diagnosed and/or communicated by the treating physicians.
Considering the marked morbidity and poor prognosis of malignant brain tumors, the consequences for the affected patients are devastating. Even with the most up-to-date treatment regimens, ,10% with high grade gliomas survive 5 years (27) . Although the use of RT generally had declined during the last decades, marked differences between countries were found. Between 2000 and 2012, the proportion of the patients who had been treated with RT in the present study spanned from 9% to 43%, with the highest numbers in the United Kingdom, reflecting national differences in the standard of care. Our previous report of a high standardized mortality ratio of 9.40 (CI, 4.50 to 17.3) (28), due to de novo brain tumors in Swedish patients with hypopituitarism, also support a more restricted use of RT. The recent availability of drugs that control hormone secretion and tumor growth in subsets of patients with pituitary adenomas (e.g., dopamine agonists and somatostatin analogs) should make this possible to achieve, although the costs of drugs as wells as lack of data on their possible metabolic long-term consequences need to be taken into account. We advocate lifelong follow-up in irradiated patients, but there is no evidence-based consensus on the surveillance interval for periodical imaging.
In the group of nonirradiated patients, the incidence of malignant brain tumors was similar to that of the general population, arguing against a substantial genetic link between pituitary tumors and malignant brain tumors. Regarding a possible coexistence between meningiomas and pituitary tumors, no conclusion can be drawn due to lack of data in the background population. We confirmed a female preponderance of meningiomas, and found no association with use of sex steroid hormone replacement therapy (29) . There was also no association between tumor development and BMI at study entry, or the dose of GH or circulating IGF-I levels during the period of observation. The possibility of a familial predisposition for brain cancers could not be determined, as there is no such information in the database. Such syndromes are rare and unlikely to contribute substantial effects.
The large number of subjects investigated and the inclusion of a comparative group of patients not given RT are strengths of this study. It is important to recognize that there is a potential limitation of using a GH treatment database; patients considered at risk for tumors may not have been replaced with GH. Furthermore, it is possible that some tumors were not captured, either because head scans were not done annually or because some lesions may have been considered small and/or stable, and not entered into the database as new tumors. This potential limitation of insufficient adverse event reporting is true of all safety surveillance databases. An additional limitation to those inherent in retrospective safety surveillance studies (as noted previously) is the incomplete details on the total and fractionated RT doses administered, as well as the dose distribution to the tumor and brain. Prospective, long-term, and ideally international protocols are warranted to determine whether the incidence of second tumors after treatment with the most modern stereotactic techniques will be lower.
RT is generally used as a second-line treatment to arrest tumor growth, or in case of secreting adenomas where hormonal control cannot be achieved after surgery and/or medical treatment. These treatment indications are still valid and useful, with extensive evidence documenting its efficacy on local tumor control and on reducing excess hormone secretion.
In summary, the present study provides robust evidence on an excess of de novo brain tumors in patients treated for pituitary adenomas, and it demonstrates a causative role of RT. Although not common, this severe consequence in patients who typically have a long life expectancy should be acknowledged, and the age of the patient should be given special consideration when balancing benefits and risks of RT.
